A Six-Person Nabilone–THC Experiment Did Not Establish Long-Term Treatment Safety
Nabilone enhanced several acute THC effects in a six-person laboratory study. Tolerability under those supervised conditions does not establish that long-term nabilone treatment makes additional cannabis use risk-free.
A drug-discrimination experiment
Six cannabis users learned to distinguish a 30-mg oral THC training dose from placebo. They then received nabilone and THC alone and in combinations. The task measured whether an internal drug experience resembled the trained THC condition; it was not a test of driving competence.
Shared cues and selective physiological effects
Nabilone produced THC-like discrimination responses and increased drug-appropriate responding when combined with THC. Some subjective and physiological effects were enhanced. Nabilone increased heart rate in selected comparisons, while blood pressure was not significantly affected.
The design cannot answer every maintenance question
Acute combinations differ from repeated maintenance treatment, where exposure, adaptation and other medicines may alter responses. The participants were selected cannabis users, the sample was extremely small, and only the tested doses and observation period were evaluated. Absence of serious events in six people cannot exclude uncommon or delayed harm.
What the study supports
The findings support further research on an agonist-treatment strategy and demonstrate that nabilone can share and enhance selected THC effects. They do not demonstrate reduced cannabis use, prevention of relapse or universal protection during a lapse. Nor can drug-discrimination responding be converted into an impairment level or a toxicology concentration. A treatment claim needs outcomes measured in a suitably designed treatment study.
Related analysis: evaluating cannabis tolerance claims.
Primary research
Lile JA; Kelly TH; Hays LR. Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC. Drug and alcohol dependence (2011). DOI: 10.1016/j.drugalcdep.2010.11.019.
